ICICI Bank, HUL, ITC help lift Sensex 177 pts, Nifty above 18,600; PSBs dip
CLOSING BELL: The S&P BSE Sensex hit a fresh life-time high at 62,887, and the Nifty 50 registered a new summit at 18,678 on Tuesday.
)
STOCK MARKET HIGHLIGHTS
The key benchmark indices extended their winning run for the sixth straight trading session, with FMCG, select IT and pharma stocks taking the lead in trades on Tuesday.
The key benchmark indices extended their winning run for the sixth straight trading session, with FMCG, select IT and pharma stocks taking the lead in trades on Tuesday.
The S&P BSE Sensex rallied to a fresh life-time high of 62,887, but pared some of the gains towards the close to finish 177 points higher at 62,682. In the process, the BSE index has rallied 1,537 points in the last six trading sessions.
The NSE Nifty advanced 55 points to a new closing high at 18,618.
Among the frontline stocks, Hindustan Unilver soared over 4 per cent to Rs 2,635. Nestle India and ITC also finished with steady gains. The Nifty FMCG index surged nearly 2 per cent to 45,078. READ MORE
Among the other Nifty 50 shares, JSW Steel jumped over 2 per cent. Cipla, Hero MotoCorp, Sun Pharma, Britannia and Dr.Reddy's were the other prominent gainers.
On the flip side, IndusInd Bank and Coal India declined around 1.5 per cent each. Bajaj Finserv, Eicher Motors and PowerGrid were the other notable losers.
The broader indices ended in red. The NSE Midcap and Smallcap were down 0.5 per cent each.
Among other individual stocks, Cosmo First surged 5.5 per cent to Rs 795. The stock has soared 17 per cent in the past two trading days, after the company announced that its board will meet on Thursday, December 1, to consider share buyback proposal. READ MORE
Meanwhile, Laurus Labs hit a 52-week low at Rs 407.40, down almost 10 per cent on margin concerns. The stock of pharmaceutical company fell below its previous low of Rs 433.20, touched on January 28, 2022. READ MORE
4:04 PM
COMMENT :: 'The future medium-term performance is a point of concern'
The ongoing domestic rally is supported by falling crude & commodity prices uplifting corporates earning outlook. However, the future medium-term performance is a point of concern due to supreme valuation. Falling raw material cost, better GDP growth and lower inflation are helping to sustain the current outperformance
Views by: Vinod Nair, Head of Research at Geojit Financial Services
Views by: Vinod Nair, Head of Research at Geojit Financial Services
4:02 PM
COMMENT :: 'Mixed global cues, hurdle around 18,700 capping upside in Nifty'
Markets extended gains for yet another session and rose nearly half a percent. After the flat start, the Nifty index gradually inched higher however profit taking in the latter half trimmed the gains. Finally, it ended at 18,618.05; up by 0.3%. Meanwhile, the sectoral indices traded mixed wherein FMCG and metal posted healthy gains. The broader indices underperformed the benchmark and shed over half a percent each.
Markets have been maintaining a positive tone, thanks to rotational buying in index majors. However, mixed global cues and the existence of a hurdle around 18700 in Nifty may cap the upside and trigger some consolidation too. Apart from banking and IT, we're seeing buying interest emerging in the defensive pack viz. FMCG and selectively in pharma. Traders should align their positions accordingly.
Views by: Ajit Mishra, VP - Technical Research, Religare Broking
Views by: Ajit Mishra, VP - Technical Research, Religare Broking
4:00 PM
IPO Update :: Dharmaj Crop issue subscribed over 5x so far on day 2
3:58 PM
Currency check :: Rupee ends lower on Tuesday
3:57 PM
ALERT :: RBI launches the first pilot for retail digital Rupee on December 1, 2022
The pilot would cover select locations in closed user group (CUG) comprising participating customers and merchants.
The e₹-R would be in the form of a digital token that represents legal tender. It would be issued in the same denominations that paper currency and coins are currently issued.
It would be distributed through intermediaries, i.e., banks. Users will be able to transact with e₹-R through a digital wallet offered by the participating banks and stored on mobile phones / devices.
Source: RBI statement
The e₹-R would be in the form of a digital token that represents legal tender. It would be issued in the same denominations that paper currency and coins are currently issued.
It would be distributed through intermediaries, i.e., banks. Users will be able to transact with e₹-R through a digital wallet offered by the participating banks and stored on mobile phones / devices.
Source: RBI statement
3:54 PM
Maha Seamless to shutdown hot mill facility; stock down 2.5%
Maharashtra Seamless to shutdown hot mill facility at Nagothane for an estimated period of 4 weeks.
3:53 PM
Gland Pharma refutes report of Promoters, Fosun Pharma, sale of shares of Company; stock up 8%
It said Gland Pharma Limited (‘the Company’) is not aware of any such information that its Promoters – Fosun Pharma and / or its Parent, Fosun International is considering sale of shares of the Company. The Company is not in receipt of any communication in this regard from its Promoter(s) and is unable to comment on the same.
3:50 PM
Gas stocks end higher on report Kirit Parekh Committee to submit report to govt tomorrow
>> Reports suggest the committee may suggest liberalising natural gas prices
3:46 PM
Cosmo First extends gains into second day, surges over 5%
Shares of Cosmo First (formerly Cosmo Films) moved higher by 8 per cent to Rs 814 on the BSE in Tuesday's intra-day trade, soaring 17 per cent in the past two trading days, after the company announced that its board will meet on Thursday, December 1, to consider share buyback proposal.
3:45 PM
Laurus Labs sinks 9%; analysts suggest more pain ahead
According to analysts at Kotak Securities, Laurus has witnessed severe pricing pressure and lower volumes in its ARV formulations portfolio for five quarters now, resulting in significant pressure on core margins.
“We believe Laurus’ troubles on ARV pricing and looming cessation of Paxlovid sales are being underappreciated. Ex-Paxlovid, it reported just a around 19 per cent EBITDA margin in 1HFY23. Even as volumes pick up, Laurus’ ARV realization will stay under pressure, as it bids for winner-takes-all tenders and lower long-term tender prices. As Paxlovid sales recede, the true extent of the margin hit will unravel,” analysts said.
“We believe Laurus’ troubles on ARV pricing and looming cessation of Paxlovid sales are being underappreciated. Ex-Paxlovid, it reported just a around 19 per cent EBITDA margin in 1HFY23. Even as volumes pick up, Laurus’ ARV realization will stay under pressure, as it bids for winner-takes-all tenders and lower long-term tender prices. As Paxlovid sales recede, the true extent of the margin hit will unravel,” analysts said.
3:43 PM
JK Tyres hits record high of Rs 204 intra-day, ends 1% up
3:42 PM
BSE SmallCap index down 0.3%, All Cargo Logistics, Hari Om Pipes top losers
3:40 PM
BSE MidCap index ends weak, dips 0.4%
3:39 PM
Sector check :: Trend largely positive; Auto, PSU Bank indicesz slip
3:37 PM
Sensex Heatmap :: HUL jumps 4%, Sun Pharma 1.5% as index ends off record highs
Topics : Stock Market MARKET LIVE MARKET WRAP Markets S&P BSE Sensex NSE Nifty Dalal Street stock market trading Oil Prices NDTV Adani Enterprises IPOs NBCC (India)
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Nov 29 2022 | 8:24 AM IST